NAD+: Benefits, Side Effects, and Dosage Chart

NAD+ benefits center on cellular energy and repair rather than anything cosmetic, the most reported side effects are flushing and nausea tied to how fast it goes in, and reported dosage varies roughly tenfold depending on the route. That last point is the one most buyers miss, and it is the reason two people following sensible protocols can be using numbers that look like they contradict each other.

One clarification first, because the search results for this compound are full of the error. NAD+ is not a peptide. It is a coenzyme, specifically a dinucleotide, with no amino acid sequence at all. It ends up shelved next to research peptides because the same vendors sell it and the same crowd buys it, not because of any chemical kinship.

What NAD+ Actually Is

Nicotinamide adenine dinucleotide is two nucleotides joined together: one carries nicotinamide, derived from vitamin B3, the other carries adenine, the same base found in DNA and ATP. Molecular weight is roughly 663 grams per mole, and research-grade material ships as a lyophilized white powder. Its stability, absorption, and side effect profile all follow from being a nucleotide rather than a protein fragment, which is why peptide handling conventions transfer only loosely.

The two roles it plays are worth keeping separate, since conflating them produces most of the bad reasoning here.

As an electron carrier, NAD+ is recycled. It accepts electrons stripped from nutrients during glycolysis and the citric acid cycle, becoming NADH, then hands them to the mitochondrial electron transport chain and reverts to NAD+. A small pool supports enormous throughput because nothing is consumed.

As a substrate, NAD+ is destroyed. Sirtuins cleave it to strip acetyl groups off proteins, PARP enzymes burn through it repairing DNA damage, and CD38 consumes it to make calcium-signaling messengers. Each reaction leaves nicotinamide behind and spends that molecule permanently, so cells rebuild supply through the salvage pathway, which recaptures nicotinamide and reassembles it.

The aging story follows from combining the two. Substrate demand rises as CD38 activity and DNA damage accumulate, while resynthesis does not keep pace. Levels drop across tissues, and since sirtuins and PARPs both depend on adequate supply, that decline plausibly degrades the cell's own maintenance machinery.

NAD+ sold as research material is not an approved drug and has no established human dosing standard. Everything below describes what has been reported, not what anyone should do.

NAD+ Benefits

The evidence base here is stronger than most of the longevity aisle, which makes the overstatement more frustrating rather than less. The mechanism is textbook biochemistry. The human outcome data is thin. Both are true.

Energy metabolism and mitochondrial function. The best-supported item, because NAD+ dependency in the electron transport chain is settled biochemistry rather than a hypothesis. Precursor supplementation has been shown to raise measurable NAD+ levels in human tissue, which is the step the rest of the argument rests on. Evidence grade: strong mechanistically, supported in humans.

DNA repair capacity. PARP1, the primary responder to routine DNA damage, runs on NAD+ and consumes large quantities when active, so lower availability slows repair. The enzyme dependency is well documented and the age-related decline in availability is measurable. Evidence grade: strong mechanistically, reasonable human support.

Sirtuin activity. Every sirtuin requires NAD+. SIRT1 is tied to metabolic regulation and inflammation, SIRT3 to mitochondrial function, SIRT6 to genome stability, and raising NAD+ raises their activity. What has not been shown is that this translates into disease prevention or extended life in people. Evidence grade: mechanism clear, human outcomes absent.

Cardiovascular and metabolic markers. Vascular tissue and insulin-responsive tissue both depend on NAD+ for the mitochondrial work they do, and small precursor studies have reported movement in surrogate markers such as arterial stiffness and muscle insulin sensitivity. The samples are small, the populations narrow, and the endpoints are markers rather than outcomes. What effect exists appears concentrated in metabolically compromised people rather than healthy ones. Evidence grade: moderate.

Muscle function and recovery. Muscle satellite cells depend on NAD+ for regenerative capacity, and the tissue is among the most mitochondria-dense in the body, so a supply decline shows up there early. Precursor studies have reported modest gains in aerobic measures and functional strength, mostly in older or deconditioned participants rather than trained ones. Evidence grade: moderate. This is where NAD+ complements MOTS-c and SS-31, which reach mitochondrial function through entirely different routes.

Cognition, inflammation, and sleep. Three areas where the mechanism outruns the data. Neurons are metabolically expensive and sensitive to NAD+ decline, which is the basis for the cognitive claims. CD38 rises with inflammation and burns NAD+ aggressively, so restoring supply activates sirtuins that dampen inflammatory signaling. NAD+ also oscillates on a 24-hour cycle through SIRT1-mediated regulation of the clock genes CLOCK and BMAL1, the likely basis for frequent reports of better sleep. Evidence grade: moderate for cognition and inflammation, emerging for sleep.

Skin, hair, and "reversing aging." No. Trial data on cosmetic outcomes is close to nonexistent, and nothing in the literature supports lifespan extension in humans or biological age reversal. Evidence grade: not supported.

The fair summary: NAD+ is a credible tool for maintaining cellular function that would otherwise decline, the healthspan argument holds up better than the lifespan argument, and the gap between rodent results and confirmed human outcomes remains wide.

NAD+ Side Effects

Most NAD+ side effects are mild, transient, and driven by administration speed rather than by the molecule itself. The exceptions are worth knowing because the compound's reputation as a harmless vitamin metabolite causes people to skip due diligence they would not skip elsewhere.

Commonly reported and generally transient. Flushing across the face, neck, and upper chest, most pronounced with niacin and fast intravenous administration. Nausea across every route, worst with high oral doses and rapid infusion. Headache, dizziness, and muscle or calf cramps, all reported across the precursor forms. Fatigue during the first week or two. Injection site burning, close to universal with subcutaneous NAD+ and usually lasting seconds to a few minutes. A jittery feeling after dosing, and insomnia when dosed in the evening.

Less common but consequential. High-dose nicotinamide has been associated with elevated liver enzymes, as has sustained high-dose niacin, while NR and NMN show minimal hepatic effects at standard doses. High precursor intakes have been linked to blood pressure reductions, which matters if you are already on antihypertensives. Rapid intravenous infusion can produce chest pressure that some describe as a deep burning sensation, resolving when the drip slows. Palpitations occur occasionally, again tied to speed. Severe allergic reactions are rare but real.

One quirk worth flagging: nicotinamide at high doses inhibits sirtuins, the very enzymes most people are targeting. It raises NAD+ and undermines the goal at the same time, which makes it a poor primary choice despite being cheap and flush-free.

Where the data is genuinely thin. Long-term safety past a few months is not well characterized for any form. Injectable and intravenous NAD+ have far less published safety work behind them than the oral precursors, and most of what exists comes from clinical practice rather than controlled trials.

Interactions and exclusions. NAD+ touches enough pathways to matter alongside diabetes medications, where improved insulin sensitivity can compound hypoglycemia risk, antihypertensives, blood thinners, cancer treatments, and high-dose antioxidants. On cancer, NAD+ does not initiate malignancy in healthy cells but can in principle support cells that already exist, which is why active treatment is a reason to defer to an oncologist rather than a supplement page. Pregnancy, breastfeeding, active liver disease, and severe kidney disease all sit outside what published data covers.

NAD+ Dosage Chart

The ranges below are what has been reported in research settings, clinical practice, and published trials of NAD+ and its precursors. They document what has been used, not what anyone should use. There is no approved human dosing standard for NAD+.

Bioavailability explains the spread. Intact NAD+ taken by mouth is largely broken down in the gut before it can be absorbed, which is why oral numbers look enormous next to injectable ones. Precursors such as NMN and NR survive that trip far better because they are smaller and get rebuilt into NAD+ inside the cell. Subcutaneous injection bypasses digestion almost entirely, and intravenous delivery skips every barrier at once.

Two things the table cannot convey. Infusion rate dominates the reported experience, and the flushing, chest pressure, and racing heartbeat people blame on NAD+ are usually the drip running too fast. And titration is standard across every route, with increases spaced a week or two apart, since body weight influences the starting point far less than delivery route does.

The clinical high-dose protocols in the last rows belong to supervised settings with monitoring. They are listed because they appear in the literature, not because they scale down to anything done at home.

Reconstitution and Storage

Lyophilized NAD+ is reconstituted with bacteriostatic water much like peptide powders, even though the chemistry differs. The arithmetic on a 1,000 mg vial is simple: 2 mL of diluent gives 500 mg per mL, putting 100 mg at 0.2 mL and 200 mg at 0.4 mL. Add diluent slowly down the vial wall rather than onto the powder, then swirl instead of shaking.

Storage is where NAD+ is less forgiving than most of what shares shelf space with it. Lyophilized material keeps best at around minus 20 degrees Celsius, desiccated and protected from light. In solution it degrades faster than typical peptides, so aliquoting and freezing is the usual approach, and solutions that develop color or cloudiness are discarded.

Two notes recur in reports of subcutaneous use: letting the vial reach room temperature before injecting reduces the sting considerably, and pushing over 20 to 30 seconds produces noticeably less burning.

Stacking

Documentation on NAD+ combinations is thinner than the stack diagrams online suggest, so this section is deliberately short.

The pairing with the clearest rationale is NAD+ or its precursors with trimethylglycine, a methyl donor. Clearing excess nicotinamide requires methylation, so sustained precursor use draws on the methyl pool, and the plateau users often report after the first couple of months is commonly attributed to this. Reported TMG use sits around 500 to 1,000 mg daily.

Within the metabolic group, NAD+ is frequently combined with MOTS-c, which works through AMPK activation, and with SS-31, which targets the inner mitochondrial membrane. 5-Amino-1MQ is the most mechanistically interesting pairing, since it inhibits NNMT, the enzyme that methylates and disposes of nicotinamide, which in principle preserves salvage pathway substrate rather than adding more from outside. Sound on paper, but controlled human data on the combination does not exist.

Combining NAD+ with high-dose antioxidants deserves care rather than enthusiasm, since the shared side effects tend to compound.

How to Verify What You Buy

Because NAD+ degrades faster than most research compounds, handling between synthesis and your door matters as much as the starting material. Ask for third-party analysis tied to your specific lot rather than a generic certificate, and confirm the vendor ships cold. Our NAD+ buying guide covers what separates credible suppliers from the rest, and the NAD+ for sale page tracks current listings and pricing.

Frequently Asked Questions

What does NAD+ do?

Two distinct things. As the NAD+/NADH redox pair it carries electrons through the reactions that produce cellular energy, and in that role it is recycled continuously. Separately it is consumed as raw material by sirtuins, by the PARP enzymes that repair DNA, and by CD38, so the cell must keep rebuilding supply. Both jobs are essential, and availability drops with age.

Is NAD+ safe?

For healthy adults at moderate doses the reported safety profile is favorable, with most effects mild and tied to delivery speed rather than dose size. That is not the same as risk-free. Long-term data past a few months is limited, high-dose nicotinamide and niacin carry dose-dependent liver considerations, and NAD+ interacts with diabetes drugs, blood thinners, antihypertensives, and cancer treatments. Injectable and intravenous forms have the least published safety work behind them.

How much NAD+ is typically used?

Almost entirely a question of route. Reported oral NAD+ use runs 500 to 1,000 mg daily, oral NMN and NR sit at 250 to 500 mg daily, subcutaneous protocols cluster at 100 to 200 mg three times weekly, and intravenous sessions are commonly 250 to 750 mg. Those are documented ranges, not recommendations.

Is NAD+ legal?

NAD+ is not a controlled substance. Oral precursors such as NR and NMN are widely sold as supplements, though regulatory treatment of NMN has shifted in some markets. Injectable NAD+ from research chemical suppliers is sold for laboratory research only and is not approved for human administration, while intravenous NAD+ is given in some clinical settings under practitioner oversight.